Company intelligence / Profile preview
Alterity Therapeutics
Melbourne, Victoria, Australiaalteritytherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company’s lead candidate, ATH434, has shown positive results in a randomized, double-blind Phase 2 trial for early-stage MSA. The study demonstrated statistically significant slowing of clinical progression at certain doses and trends toward improved motor performance. An open-label Phase 2 trial in advanced MSA has completed last patient visit with topline data expected mid-year 2025. Orphan Drug designation has been granted by both FDA and EMA for MSA.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Michael J. Fox Foundation funding support for dose optimization studies in Parkinson's disease; no major pharma partnerships disclosed as of latest updates.
Beyond the preview
Go deeper on Alterity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alterity Therapeutics.